
    
      The objective is to evaluate the safety of intravitreal Fovista速 (anti-PDGF BB) administered
      in combination with anti-VEGF therapy in either a "Simultaneous" Regimen (Fovista速
      administered with anti-VEGF same day) or "Pre-Treatment" Regimen (monotherapy Fovista速 Day 0
      followed by Fovista速 administered in combination with anti-VEGF Day 2).
    
  